Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Guardant Health, Inc.    GH

GUARDANT HEALTH, INC.

(GH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/01/2021 03/02/2021 03/03/2021 03/04/2021 03/05/2021 Date
152.14(c) 154.63(c) 143.7(c) 133.15(c) 135.27(c) Last
671 111 1 123 237 1 327 452 1 739 146 2 163 895 Volume
+3.37% +1.64% -7.07% -7.34% +1.59% Change
More quotes
Financials (USD)
Sales 2021 369 M - -
Net income 2021 -309 M - -
Net cash position 2021 972 M - -
P/E ratio 2021 -47,8x
Yield 2021 -
Sales 2022 508 M - -
Net income 2022 -279 M - -
Net cash position 2022 828 M - -
P/E ratio 2022 -50,6x
Yield 2022 -
Capitalization 13 585 M 13 585 M -
EV / Sales 2021 34,2x
EV / Sales 2022 25,1x
Nbr of Employees 864
Free-Float 93,8%
More Financials
Company
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and... 
More about the company
Notations Surperformance© of Guardant Health, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about GUARDANT HEALTH, INC.
03/02GUARDANT HEALTHá : Obtains CE Mark For Tumor Mutation Profiling Test
MT
03/02GUARDANT HEALTHá : Guardant360« CDx Liquid Biopsy CE-Marked for Comprehensive Tu..
BU
02/26GUARDANT HEALTHá : Morgan Stanley Adjusts Guardant Health's Price Target to $175..
MT
02/25GUARDANT HEALTHá : Management's Discussion and Analysis of Financial Condition a..
AQ
02/25GUARDANT HEALTHá : Cowen Adjusts Guardant Health's Price Target to $190 from $14..
MT
02/25GUARDANT HEALTHá : Citigroup Adjusts Price Target on Guardant Health to $190 Fro..
MT
02/24GUARDANT HEALTH : 4Q Earnings Snapshot
AQ
02/24GUARDANT HEALTHá : Logs Wider Q4 Net Loss; Shares Down Late as FY21 Sales View L..
MT
02/24GUARDANT HEALTH, INC.á : Results of Operations and Financial Condition (form 8-K..
AQ
02/24GUARDANT HEALTHá : Earnings Flash (GH) GUARDANT HEALTH Posts Q4 Revenue $78.3M, ..
MT
02/24GUARDANT HEALTHá : Reports Fourth Quarter and Full Year 2020 Financial Results a..
BU
02/17GUARDANT HEALTHá : to Participate in Upcoming Investor Conferences
BU
02/16GUARDANT HEALTHá : Launches Guardant Reveal™ Liquid Biopsy Test for Residu..
BU
02/04GUARDANT HEALTHá : to Report Fourth Quarter and Full Year 2020 Financial Results..
BU
01/27GUARDANT HEALTHá : Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperform..
BU
More news
News in other languages on GUARDANT HEALTH, INC.
03/03GUARDANT HEALTHá : Guardant360« CDx Liquid Biopsy erhält die CE-Zertifizierung f..
03/02GUARDANT HEALTHá : La biopsie liquide Guardant360« CDx obtient le marquage CE po..
01/19GUARDANT HEALTHá : und das Vall d'Hebron Institute of Oncology geben Partnerscha..
01/19GUARDANT HEALTHá : et l'Institut d'oncologie de Vall d'Hebron annoncent un parte..
2019Vision Fund veut garantir un prêt par ses parts dans Uber
More news
Analyst Recommendations on GUARDANT HEALTH, INC.
More recommendations
Chart GUARDANT HEALTH, INC.
Duration : Period :
Guardant Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GUARDANT HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 170,45 $
Last Close Price 135,27 $
Spread / Highest target 44,2%
Spread / Average Target 26,0%
Spread / Lowest Target -38,6%
EPS Revisions
Managers and Directors
NameTitle
Helmy Eltoukhy Chief Executive Officer & Director
AmrAli H. Talasaz Chairman, President & Chief Operations Officer
Michael Bell Chief Financial Officer
Kumud Kalia Chief Information Officer
Darya Chudova Senior Vice President-Technology
Sector and Competitors
1st jan.Capitalization (M$)
GUARDANT HEALTH, INC.3.31%13 585
EXACT SCIENCES CORPORATION-4.47%20 568
BGI GENOMICS CO., LTD.1.61%8 244
INVITAE CORPORATION-18.34%6 714
ADAPTIVE BIOTECHNOLOGIES CORPORATION-26.13%5 879
IOVANCE BIOTHERAPEUTICS, INC.-31.53%4 756